Biotech | March 31, 2022
BioVaxys expands cancer vaccine platform
BVX-0922 to target colorectal cancer under investigator-sponsored IND
BVX-0922 to target colorectal cancer under investigator-sponsored IND
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
Paige Breast Lymph Node designed to enhance diagnostic accuracy and confidence detecting breast cancer metastases of any size in lymph node tissue
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
Tislelizumab is now approved for seven indications in China
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
The approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
Subscribe To Our Newsletter & Stay Updated
